Cost-effectiveness of neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab for high-risk early-stage triple-negative breast cancer in Colombia

被引：0
|
作者：
Bruges Maya, R. [1 ]
Urrego, J. C. [2 ]
Marrugo, C. [2 ]
Wurcel, V. [3 ]
Khandelwal, A. [4 ]
Singh, J. [4 ]
Huang, M. [5 ]
Haiderali, A. [6 ]
机构：
[1] Ctr Javeriano Oncol Hosp San Ignacio, Clin Oncol, Bogota, Colombia
[2] MSD Colombia, Market Access, Bogota, Colombia
[3] MSD Argentina, CABA, Munro, Argentina
[4] CHEORS Complete Hlth Econ Outcomes & Res Solut, Econ Modeling & Adaptat, North Wales, PA USA
[5] Merck & Co Inc, Econ & Data Sci, Rahway, NJ USA
[6] Merck & Co Inc, Ctr Observat & Real World Evidence, Rahway, NJ USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.455
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
258P
引用
收藏
页码：S286 / S286
页数：1
相关论文
共 50 条
  • [1] Cost-Effectiveness of Neoadjuvant Pembrolizumab plus Chemotherapy Followed by Adjuvant Pembrolizumab in Patients with High-Risk, Early-Stage, Triple-Negative Breast Cancer in Switzerland
    Andrea Favre-Bulle
    Min Huang
    Amin Haiderali
    Arjun Bhadhuri
    [J]. PharmacoEconomics - Open, 2024, 8 : 91 - 101
  • [2] Cost-Effectiveness of Neoadjuvant Pembrolizumab plus Chemotherapy Followed by Adjuvant Pembrolizumab in Patients with High-Risk, Early-Stage, Triple-Negative Breast Cancer in Switzerland
    Favre-Bulle, Andrea
    Huang, Min
    Haiderali, Amin
    Bhadhuri, Arjun
    [J]. PHARMACOECONOMICS-OPEN, 2024, 8 (01) : 91 - 101
  • [3] Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer in the United States
    Min Huang
    Peter A. Fasching
    Amin Haiderali
    Weiguang Xue
    Chelsey Yang
    Wilbur Pan
    Zheng-Yi Zhou
    Peter Hu
    Mitashri Chaudhuri
    Celine Le Bailly De Tilleghem
    Nicolas Cappoen
    Joyce O’Shaughnessy
    [J]. Advances in Therapy, 2023, 40 : 1153 - 1170
  • [4] Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer in the United States
    Huang, Min
    A. Fasching, Peter
    Haiderali, Amin
    Xue, Weiguang
    Yang, Chelsey
    Pan, Wilbur
    Zhou, Zheng-Yi
    Hu, Peter
    Chaudhuri, Mitashri
    De Tilleghem, Celine Le Bailly
    Cappoen, Nicolas
    O'Shaughnessy, Joyce
    [J]. ADVANCES IN THERAPY, 2023, 40 (03) : 1153 - 1170
  • [5] COST-EFFECTIVENESS OF NEOADJUVANT PEMBROLIZUMAB PLUS CHEMOTHERAPY FOLLOWED BY ADJUVANT PEMBROLIZUMAB FOR HIGH-RISK EARLYSTAGE TRIPLE-NEGATIVE BREAST CANCER (ETNBC) IN FRANCE
    Cagnan, L.
    Haiderali, A.
    Bensimon, L.
    Tehard, B.
    Carita, M.
    Khandelwal, A.
    Gandhi, J.
    Huang, M.
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S61 - S61
  • [6] COST-EFFECTIVENESS OF NEOADJUVANT PEMBROLIZUMAB PLUS CHEMOTHERAPY FOLLOWED BY ADJUVANT PEMBROLIZUMAB FOR HIGH-RISK EARLYSTAGE TRIPLE NEGATIVE BREAST CANCER IN COSTA RICA
    Rendon, A. M.
    Cordoba, R.
    Wurcel, V
    Rubino, R.
    Junqueira, M.
    Haiderali, A.
    Huang, M.
    Khandelwal, A.
    Gotarkar, S.
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S152 - S152
  • [7] Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab for treatment of high-risk, early-stage triple-negative breast cancer: A network meta-analysis
    Cortes, J.
    Haiderali, A.
    Huang, M.
    Pan, W.
    Fox, G. E.
    Park, J.
    Frederickson, A. M.
    Fasching, P. A.
    O'Shaughnessy, J.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S615 - S616
  • [8] Letter to the Editor Regarding "Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single Agent Pembrolizumab for High-Risk Early-Stage Triple Negative Breast Cancer in the United States"
    Sorscher, Steven
    [J]. ADVANCES IN THERAPY, 2023, 40 (09) : 4111 - 4113
  • [9] Letter to the Editor Regarding “Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single Agent Pembrolizumab for High-Risk Early-Stage Triple Negative Breast Cancer in the United States”
    Steven Sorscher
    [J]. Advances in Therapy, 2023, 40 : 4111 - 4113
  • [10] COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB PLUS CHEMOTHERAPY AS NEOADJUVANT THERAPY AND CONTINUED AS A SINGLE AGENT AS ADJUVANT THERAPY FOR HIGH-RISK EARLY-STAGE TRIPLE-NEGATIVE BREAST CANCER IN GREECE
    Yfantopoulos, N.
    Athanasopoulos, C.
    Haiderali, A.
    Huang, M.
    Gountas, I
    Skroumpelos, A.
    Karokis, A.
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S91 - S91
12345